Classification of mitocans, anti-cancer drugs acting on mitochondria

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F86652036%3A_____%2F13%3A00393079" target="_blank" >RIV/86652036:_____/13:00393079 - isvavai.cz</a>
Result on the web
<a href="http://dx.doi.org/10.1016/j.mito.2012.07.112" target="_blank" >http://dx.doi.org/10.1016/j.mito.2012.07.112</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.mito.2012.07.112" target="_blank" >10.1016/j.mito.2012.07.112</a>

Result language
angličtina
Original language name
Classification of mitocans, anti-cancer drugs acting on mitochondria
Original language description
Mitochondria have emerged as an intriguing target for anti-cancer drugs, inherent to vast majority if not all types of tumours. Drugs that target mitochondria and exert anti-cancer activity have become a focus of recent research due to their great clinical potential (which has not been harnessed thus far). The exceptional potential of mitochondria as a target for anti-cancer agents has been reinforced by the discouraging finding that even turnouts of the same type from individual patients differ in a number of mutations. This is consistent with the idea of personalised therapy, an elusive goal at this stage, in line with the notion that tumours are unlikely to be treated by agents that target only a single gene or a single pathway. This endows mitochondria, an invariant target present in all tumours, with an exceptional momentum. This train of thoughts inspired us to define a class of anti-cancer drugs acting by way of mitochondria 'destabilisation', termed 'mitocans'. In this communic
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
EB - Genetics and molecular biology
OECD FORD branch
—

Publication year
2013
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)